featured
2020 Top Stories in Advanced Prostate Cancer: PARP Inhibitors in Advanced Prostate Cancer With DNA Repair Defects
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102.
- Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26(11):2487-2496.
Disclosure statements are available on the authors' profiles:
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.